LivaNova (NASDAQ:LIVN) Price Target Raised to $73.00 at Barclays

LivaNova (NASDAQ:LIVN) had its price objective increased by Barclays from $67.00 to $73.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday. Needham & Company LLC raised their target price on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday. KeyCorp initiated coverage on LivaNova in a research note on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Mizuho lifted their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $74.78.

LivaNova Trading Down 0.6%

Shares of LIVN stock traded down $0.40 during trading hours on Friday, reaching $70.60. 945,849 shares of the stock were exchanged, compared to its average volume of 872,518. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of -15.83 and a beta of 0.97. LivaNova has a 12-month low of $32.48 and a 12-month high of $71.92. The company’s 50-day moving average price is $64.74 and its 200-day moving average price is $59.04. The company has a current ratio of 1.36, a quick ratio of 1.12 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. The business had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, equities analysts anticipate that LivaNova will post 2.85 earnings per share for the current year.

Institutional Trading of LivaNova

A number of hedge funds have recently modified their holdings of LIVN. Artisan Partners Limited Partnership lifted its holdings in LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares during the period. Wellington Management Group LLP grew its stake in shares of LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares during the period. Invesco Ltd. lifted its stake in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after purchasing an additional 902,447 shares during the period. Scopia Capital Management LP acquired a new position in shares of LivaNova in the 2nd quarter valued at $36,657,000. Finally, Millennium Management LLC boosted its holdings in LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after buying an additional 544,033 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.